Enhancing CRISPR-mediated site-specific transgene insertion efficiency by homology-directed
repair (HDR) using high concentrations of double-stranded DNA (dsDNA) with Cas9 …

The myeloma surface proteome (surfaceome) determines tumor interaction with the
microenvironment and serves as an emerging arena for therapeutic development. Here, we use …

Chimeric antigen receptors (CARs) repurpose natural signaling components to retarget T cells
to refractory cancers but have shown limited efficacy in persistent, recurrent malignancies. …

Central nervous system involvement by malignant cells is a rare complication of Waldenström
macroglobulinemia, and this clinicopathological entity is referred to as the Bing-Neel …

B cell progenitor acute lymphoblastic leukemia (B-ALL) treatment has been revolutionized
by T cell-based immunotherapies—including chimeric antigen receptor T cell therapy (CAR-T) …

Precise targeting of large transgenes to T cells using homology-directed repair has been
transformative for adoptive cell therapies and T cell biology. Delivery of DNA templates via …

Proteasome inhibitors (PIs) are a fascinating class of small molecules that disrupt protein
homeostasis and are highly efficacious in the blood cancer multiple myeloma. However, PIs …

Multiple myeloma (MM) is a currently incurable malignancy of antibody-secreting plasma
cells. Long non-coding RNAs (lncRNAs) have been recognised as an important class of …

Cytogenetic abnormalities (CAs) are known to be the preponderant prognostic factor in
multiple myeloma. Our team has recently developed a prognostic score based on 6 CAs, with …

Background Preemptive rituximab (R) treatment decreases the incidence of Epstein-Barr
virus (EBV) posttransplantation lymphoproliferative disease, but the extent of immune …